Can a Weight-Loss drug slow prostate cancer? a trial investigates

NCT ID NCT07727473

NEW Not yet recruiting Disease control Sponsor: Banner Health Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 27, 2026

Summary

This trial explores whether semaglutide, a drug approved for weight management, can affect tumor biology when given for 3 to 6 months before prostate removal surgery. About 20 men with intermediate-risk localized prostate cancer and a BMI over 35 will receive weekly injections. Researchers will measure changes in tumor cell activity and cancer markers in tissue samples taken before and after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide, a GLP-1 receptor agonist drug used for weight management
What this could lead to
If semaglutide shows anti-tumor activity, it could point toward a new treatment approach for prostate cancer that also improves metabolic health.
What could go wrong
This is a very early, small trial with only 20 participants and no comparison group. The drug is being tested for its effect on tumor markers, not for curing cancer, and may cause side effects like nausea or gastrointestinal issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERMEDIATE-RISK LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Banner MD Anderson Cancer Center at Gateway

    Gilbert, Arizona, 85234, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.